Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia

BASKING RIDGE, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
April 09, 2018 16:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Participate at Upcoming April Conferences

BASKING RIDGE, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
April 03, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at The MicroCap Conference

BASKING RIDGE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 22, 2018 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results

BASKING RIDGE, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 15, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 13, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan

BASKING RIDGE, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 08, 2018 16:05 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

BASKING RIDGE, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 08, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes

BASKING RIDGE, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
March 06, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina

BASKING RIDGE, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...
February 07, 2018 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple...